Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1398309
PUBLISHER: GlobalData | PRODUCT CODE: 1398309
Drug Eluting Stents (DES) Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
PUBLISHED:
PAGES: 152 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Abstract
GlobalData's Medical Devices sector report, "Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Drug Eluting Stents (DES) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2 Introduction
- 2.1 Drug Eluting Stents (DES) Overview
3 Products under Development
- 3.1 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
- 3.2 Drug Eluting Stents (DES) - Pipeline Products by Territory
- 3.3 Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
- 3.4 Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
- 3.5 Drug Eluting Stents (DES) - Ongoing Clinical Trials
4 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies
- 4.1 Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
- 4.2 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
5 Drug Eluting Stents (DES) Companies and Product Overview
- 5.1 Abbott Vascular Inc Company Overview
- 5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.2 Adcomp Technologies Inc. Company Overview
- 5.2.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
- 5.3 Advanced Bifurcation Systems Inc Company Overview
- 5.3.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.4 Aeon Bioscience Company Overview
- 5.4.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
- 5.5 B. Braun Melsungen AG Company Overview
- 5.5.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
- 5.6 Biosensors International Group Ltd Company Overview
- 5.6.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.7 Biotronik AG Company Overview
- 5.7.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
- 5.8 Biotronik SE & Co KG Company Overview
- 5.8.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
- 5.9 Boston Scientific Corp Company Overview
- 5.9.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.10 Cardionovum GmbH Company Overview
- 5.10.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
- 5.11 Cardiorev Pte Ltd (Inactive) Company Overview
- 5.11.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
- 5.12 Columbia University Company Overview
- 5.12.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
- 5.13 Concept Medical Inc Company Overview
- 5.13.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.14 Cordis Corp Company Overview
- 5.14.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.15 DISA Vascular (Pty) Ltd Company Overview
- 5.15.1 DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.16 Elixir Medical Corp Company Overview
- 5.16.1 Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.17 Endomimetics LLC Company Overview
- 5.17.1 Endomimetics LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.18 Envision Scientific Pvt Ltd Company Overview
- 5.18.1 Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.19 I.B.S. S.p.A. Company Overview
- 5.19.1 I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
- 5.20 InspireMD Inc Company Overview
- 5.20.1 InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.21 JW Medical Systems Ltd Company Overview
- 5.21.1 JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.22 Kaneka Corp Company Overview
- 5.22.1 Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.23 MangoGen Pharma Inc Company Overview
- 5.23.1 MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.24 Medinol Ltd Company Overview
- 5.24.1 Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.25 Medlogics Device Corp (Inactive) Company Overview
- 5.25.1 Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
- 5.26 Medtronic Plc Company Overview
- 5.26.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
- 5.27 MicroPort Scientific Corp Company Overview
- 5.27.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.28 MIV Therapeutics Inc Company Overview
- 5.28.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.29 Northwestern University Company Overview
- 5.29.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
- 5.30 NuVascular Technologies Inc Company Overview
- 5.30.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.31 Relisys Medical Devices Ltd Company Overview
- 5.31.1 Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.32 REVA Medical Inc Company Overview
- 5.32.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.33 Shandong Rientech Medical Tech Co Ltd Company Overview
- 5.33.1 Shandong Rientech Medical Tech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.34 Shanghai BIOMAGIC Medical Device Co Ltd Company Overview
- 5.34.1 Shanghai BIOMAGIC Medical Device Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.35 Shanghai MicroPort Medical Group Co Ltd Company Overview
- 5.35.1 Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.36 Sino Medical Sciences Technology Inc Company Overview
- 5.36.1 Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.37 Stentys SA Company Overview
- 5.37.1 Stentys SA Pipeline Products & Ongoing Clinical Trials Overview
- 5.38 Svelte Medical Systems Inc Company Overview
- 5.38.1 Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.39 Terumo Corp Company Overview
- 5.39.1 Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
- 5.40 Terumo Interventional Systems Company Overview
- 5.40.1 Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview
- 5.41 TissueGen Inc Company Overview
- 5.41.1 TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.42 Translumina Therapeutics LLP Company Overview
- 5.42.1 Translumina Therapeutics LLP Pipeline Products & Ongoing Clinical Trials Overview
- 5.43 University of Strathclyde Company Overview
- 5.43.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
- 5.44 VasoTech Inc. Company Overview
- 5.44.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
6 Drug Eluting Stents (DES)- Recent Developments
7 Appendix
- 7.1 Methodology
- 7.2 About GlobalData
- 7.3 Contact Us
- 7.4 Disclaimer
List of Tables
List of Tables
- Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
- Drug Eluting Stents (DES) - Pipeline Products by Territory
- Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
- Drug Eluting Stents (DES) - Pipeline Products
List of Figures
List of Figures
- Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
- Drug Eluting Stents (DES) - Pipeline Products by Territory
- Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
- Drug Eluting Stents (DES) - Pipeline Products
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.